LON:NFXNuformix Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nuformix PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 4.30 -0.25 (-5.49 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range 4.22Now: GBX 4.30▼ 4.6450-Day Range 4.10MA: GBX 5.15▼ 6.6052-Week Range 3.33Now: GBX 4.30▼ 14.89Volume3.71 million shsAverage Volume1.13 million shsMarket Capitalization£21.08 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesOptions Chain Nuformix plc develops pharmaceutical products using its cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP003, which is under the pre-clinical stage for the treatment of anti-inflammatory diseases. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nuformix. Previous Next 2.5 Community Rank Outperform VotesNuformix has received 68 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNuformix has received 68 “underperform” votes. (Add your “underperform” vote.)Community SentimentNuformix has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nuformix and other stocks. Vote “Outperform” if you believe NFX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NFX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNuformix does not currently pay a dividend.Dividend GrowthNuformix does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuformix insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuformix is -21.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuformix is -21.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuformix has a P/B Ratio of 5.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:NFX Previous SymbolLON:LVRT CUSIPN/A CIKN/A Webwww.levrett.com Phone44 1223 423 667Debt Debt-to-Equity Ratio0.38 Current Ratio0.47 Quick Ratio0.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£535,000.00 Price / Sales39.39 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 0.80 per share Price / Book5.38Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees3 Outstanding Shares490,144,992Market Cap£21.08 million Next Earnings DateN/A OptionableOptionable LSE:NFX Rates by TradingView Receive NFX News and Ratings via Email Sign-up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter. Nuformix (LON:NFX) Frequently Asked Questions How has Nuformix's stock been impacted by COVID-19 (Coronavirus)? Nuformix's stock was trading at GBX 5.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NFX stock has decreased by 21.8% and is now trading at GBX 4.30. View which stocks have been most impacted by Coronavirus. Has Nuformix been receiving favorable news coverage? Media coverage about NFX stock has been trending extremely negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Nuformix earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutNuformix. Who are some of Nuformix's key competitors? Some companies that are related to Nuformix include Cohbar (CWBR), 22nd Century Group (XXII), Ampliphi Biosciences (APHB), Altimmune (ALT), iShares Diversified Alternatives Trust (ALT), Ibio (IBIO), Circassia Pharmaceuticals (CIR), Orgenesis (ORGS), Ampio Pharmaceuticals (AMPE), Novoheart (NVH), Immunoprecise Antibodies (IPA), Omega Diagnostics Group (ORPH), Ampio Pharmaceuticals (AMPE), Acasti Pharma (ACST) and Biopharmx (BPMX). View all competitors. What other stocks do shareholders of Nuformix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nuformix investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquantia (AQ) and Aquinox Pharmaceuticals (AQXP). Who are Nuformix's key executives? Nuformix's management team includes the following people: Dr. Daniel John Gooding, CEO & Director (Age 45)Dr. Joanne M. Holland, Chief Scientific Officer & Director (Age 44) What is Nuformix's stock symbol? Nuformix trades on the London Stock Exchange (LON) under the ticker symbol "NFX." How do I buy shares of Nuformix? Shares of NFX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Nuformix's stock price today? One share of NFX stock can currently be purchased for approximately GBX 4.30. How big of a company is Nuformix? Nuformix has a market capitalization of £21.08 million and generates £535,000.00 in revenue each year. Nuformix employs 3 workers across the globe. What is Nuformix's official website? The official website for Nuformix is www.levrett.com. How can I contact Nuformix? Nuformix's mailing address is Ste 31 Second Fl, 107 Cheapside, LONDON, EC2V 6DN, United Kingdom. The company can be reached via phone at 44 1223 423 667. This page was last updated on 5/29/2020 by MarketBeat.com Staff
